PL2504336T3 - Nowe pochodne naftyrydynowe i ich zastosowanie jako inhibitorów kinaz - Google Patents

Nowe pochodne naftyrydynowe i ich zastosowanie jako inhibitorów kinaz

Info

Publication number
PL2504336T3
PL2504336T3 PL10782280.1T PL10782280T PL2504336T3 PL 2504336 T3 PL2504336 T3 PL 2504336T3 PL 10782280 T PL10782280 T PL 10782280T PL 2504336 T3 PL2504336 T3 PL 2504336T3
Authority
PL
Poland
Prior art keywords
kinase inhibitors
naphthyridine derivatives
new
new naphthyridine
derivatives
Prior art date
Application number
PL10782280.1T
Other languages
English (en)
Inventor
Tilmann Schuster
Matthias Gerlach
Irene Seipelt
Emmanuel Polymeropoulos
Gilbert Müller
Eckhard Günther
Pascal Marchand
Julien Defaux
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of PL2504336T3 publication Critical patent/PL2504336T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B55/00—Racemisation; Complete or partial inversion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL10782280.1T 2009-11-26 2010-11-24 Nowe pochodne naftyrydynowe i ich zastosowanie jako inhibitorów kinaz PL2504336T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09177132A EP2332939A1 (en) 2009-11-26 2009-11-26 Novel Naphthyridine derivatives and the use thereof as kinase inhibitors
US26471109P 2009-11-27 2009-11-27

Publications (1)

Publication Number Publication Date
PL2504336T3 true PL2504336T3 (pl) 2016-10-31

Family

ID=41793139

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10782280.1T PL2504336T3 (pl) 2009-11-26 2010-11-24 Nowe pochodne naftyrydynowe i ich zastosowanie jako inhibitorów kinaz

Country Status (19)

Country Link
US (1) US8461178B2 (pl)
EP (2) EP2332939A1 (pl)
JP (1) JP5726202B2 (pl)
KR (1) KR20120096545A (pl)
CN (1) CN102666536B (pl)
AR (1) AR079131A1 (pl)
AU (1) AU2010323137B2 (pl)
BR (1) BR112012012694A2 (pl)
CA (1) CA2781818A1 (pl)
ES (1) ES2573665T3 (pl)
IL (1) IL219646A0 (pl)
MX (1) MX345495B (pl)
NZ (1) NZ600042A (pl)
PH (1) PH12012500921A1 (pl)
PL (1) PL2504336T3 (pl)
RU (1) RU2573390C2 (pl)
TW (1) TWI508963B (pl)
WO (1) WO2011064250A1 (pl)
ZA (1) ZA201202906B (pl)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
GB201020179D0 (en) 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
WO2013018733A1 (ja) 2011-07-29 2013-02-07 富士フイルム株式会社 １，５－ナフチリジン誘導体又はその塩
GB201118675D0 (en) * 2011-10-28 2011-12-14 Astex Therapeutics Ltd New compounds
GB201118652D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118654D0 (en) * 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118656D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
CN103183674B (zh) * 2011-12-31 2017-09-12 江苏先声药业有限公司 一类稠杂环衍生物及其应用
DK2753329T3 (en) 2012-01-19 2017-10-23 Onco Therapy Science Inc 1,5-NAPHTHYRIDINE INGREDIENTS AS MILK INHIBITORS
GB201209613D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
GB201209609D0 (en) * 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
US9611267B2 (en) 2012-06-13 2017-04-04 Incyte Holdings Corporation Substituted tricyclic compounds as FGFR inhibitors
CN104903320B (zh) 2013-01-11 2018-11-13 富士胶片株式会社 含氮杂环化合物或其盐
TWI649318B (zh) * 2013-04-19 2019-02-01 英塞特控股公司 作為ｆｇｆｒ抑制劑之雙環雜環
GB201307577D0 (en) 2013-04-26 2013-06-12 Astex Therapeutics Ltd New compounds
HUE053654T2 (hu) 2014-03-26 2021-07-28 Astex Therapeutics Ltd FGFR- és CMET-inhibitorok kombinációi a rák kezelésére
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
KR102479696B1 (ko) 2014-03-26 2022-12-22 아스텍스 테라퓨틱스 리미티드 Fgfr 억제제 및 igf1r 억제제의 조합물
JOP20200201A1 (ar) 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
AU2016219822B2 (en) 2015-02-20 2020-07-09 Incyte Holdings Corporation Bicyclic heterocycles as FGFR inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
EP3353164B1 (en) 2015-09-23 2021-11-03 Janssen Pharmaceutica, N.V. Bi-heteroaryl substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer
CA2996857C (en) 2015-09-23 2024-05-21 Janssen Pharmaceutica Nv Quinoxaline, quinoline and quinazolinone derivative compounds for the treatment of cancer
KR20180100227A (ko) * 2016-01-11 2018-09-07 메르크 파텐트 게엠베하 퀴놀린-2-온 유도체
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
ES2991427T3 (es) 2018-05-04 2024-12-03 Incyte Corp Formas sólidas de un inhibidor de FGFR y procedimientos para preparar las mismas
TW201946630A (zh) 2018-05-04 2019-12-16 美商英塞特公司 Fgfr抑制劑之鹽
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
GEAP202415945A (en) 2019-10-14 2024-04-25 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
AU2020395185A1 (en) 2019-12-04 2022-06-02 Incyte Corporation Derivatives of an FGFR inhibitor
CA3163875A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
EP4323405A1 (en) 2021-04-12 2024-02-21 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
AR126101A1 (es) 2021-06-09 2023-09-13 Incyte Corp Heterociclos tricíclicos como inhibidores de fgfr
CA3220274A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
CN115806523B (zh) * 2022-11-24 2024-11-22 贵州医科大学 一种取代喹啉化合物及其在制备抗肿瘤药物中的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2650826A1 (de) 1976-11-06 1978-05-11 Merck Patent Gmbh Cephemderivate
EP1075478B1 (en) 1998-05-08 2003-04-16 SmithKline Beecham plc Phenylurea and phenylthio urea derivatives
GB9822440D0 (en) 1998-10-14 1998-12-09 Smithkline Beecham Plc Medicaments
EP1144404A1 (en) 1999-01-20 2001-10-17 Smithkline Beecham Plc Piperidinylquinolines as protein tyrosine kinase inhibitors
PT1171440E (pt) 1999-04-21 2004-07-30 Wyeth Corp 3-ciano-¬1,7|,¬1,5|, e ¬1,8|-naftiridinas substituidas inibidoras de tirosina quinases
GB9917408D0 (en) 1999-07-23 1999-09-22 Smithkline Beecham Plc Compounds
IL154107A0 (en) 2000-07-26 2003-07-31 Smithkline Beecham Plc Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity
GB0101577D0 (en) 2001-01-22 2001-03-07 Smithkline Beecham Plc Compounds
US6822097B1 (en) * 2002-02-07 2004-11-23 Amgen, Inc. Compounds and methods of uses
WO2004050659A1 (en) * 2002-11-27 2004-06-17 Eli Lilly And Company Novel compounds as pharmaceutical agents
DE102004041163A1 (de) 2004-08-25 2006-03-02 Morphochem Aktiengesellschaft für kombinatorische Chemie Neue Verbindungen mit antibakterieller Aktivität
US7501395B2 (en) 2005-04-25 2009-03-10 Eisai R & D Management Co., Ltd. Method of screening for antianxiety drugs
MX2009012765A (es) 2007-05-25 2009-12-16 Janssen Pharmaceutica Nv Moduladores de urea con heteroarilo sustituido de acido graso amida hidrolasa.
WO2008150827A1 (en) 2007-05-29 2008-12-11 Smithkline Beecham Corporation Naphthyridine, derivatives as p13 kinase inhibitors
GB0801416D0 (en) * 2008-01-25 2008-03-05 Piramed Ltd Pharmaceutical compounds
US8455648B2 (en) * 2008-04-24 2013-06-04 Abbott Gmbh & Co. Kg 1-(7-(hexahydropyrrolo [3,4-c] pyrrol-2 (1H)-yl) quinolin-4-yl) -3- (pyrazin-2-yl) urea derivatives and related compounds as glycogen synthase kinase 3 (GSK-3)

Also Published As

Publication number Publication date
AR079131A1 (es) 2011-12-28
TW201121972A (en) 2011-07-01
IL219646A0 (en) 2012-07-31
KR20120096545A (ko) 2012-08-30
ZA201202906B (en) 2012-12-27
EP2332939A1 (en) 2011-06-15
JP2013512217A (ja) 2013-04-11
RU2573390C2 (ru) 2016-01-20
EP2504336B1 (en) 2016-03-30
HK1170737A1 (zh) 2013-03-08
US20110150831A1 (en) 2011-06-23
TWI508963B (zh) 2015-11-21
AU2010323137B2 (en) 2014-04-10
ES2573665T3 (es) 2016-06-09
BR112012012694A2 (pt) 2019-09-24
JP5726202B2 (ja) 2015-05-27
MX2012006154A (es) 2012-06-28
CN102666536A (zh) 2012-09-12
CA2781818A1 (en) 2011-06-03
MX345495B (es) 2017-02-02
PH12012500921A1 (en) 2016-06-10
EP2504336A1 (en) 2012-10-03
CN102666536B (zh) 2016-03-30
NZ600042A (en) 2014-05-30
RU2012120288A (ru) 2014-01-10
AU2010323137A1 (en) 2012-06-07
US8461178B2 (en) 2013-06-11
WO2011064250A1 (en) 2011-06-03

Similar Documents

Publication Publication Date Title
PL2504336T3 (pl) Nowe pochodne naftyrydynowe i ich zastosowanie jako inhibitorów kinaz
FR25C1006I2 (fr) Inhibiteurs de pyrazolyl-quinoxaline kinase
BRPI0916295A2 (pt) inibidores de pirazolopiridina tricíclica cinase
PT2624696T (pt) Derivados de benzimidazole como inibidores da cinase pi3
EP2632898A4 (en) HETEROCYCLIC TYROSINE KINASE HEMMER
PL2456444T3 (pl) Pochodne adeniny jako inhibitory PI3K
ZA201405140B (en) Disubstituted benzothienyl-pyrolotriazines and their use as fgfr kinase inhibitors
ZA201206257B (en) N-(imidazopyrimidin-7yl)-heteroarylamide derivatives and their use as pde10a inhibitors
DK2406253T3 (da) Benzofuranylderivater anvendt som glucokinase-inhibitorer
DK2751102T3 (da) Forbindelser og sammensætninger som C-kit-kinasehæmmere
IL221823A (en) Pipridine-4-Il-Aztidine Derivatives as Jack 1 Suppressors
PL2480546T3 (pl) Pochodne imidazopirydyny i imidazopirymidyny jako inhibitory fosfodiesterazy 10A
DK2513105T3 (da) 2-arylimidazolderivater som pde10a-enzyminhibitorer
IL211549A0 (en) Aminotriazolopyridines and their use as kinase inhibitors
IL216411A0 (en) Pyrazolopyrimidines and related heterocycles as kinase inhibitors
IL212842A0 (en) Azaindole derivatives as kinase inhibitors
DK2513106T3 (da) Heteroaromatiske aryltriazol-derivater som pde10a-enzyminhibitorer
IL212755A0 (en) Pyrazinopyrazines and derivatives as kinase inhibitors
PT3070091T (pt) Derivados do benzodioxole como inibidores da fosfodiesterase
ZA201300036B (en) Banzamide derivatives and their use as hsp90 inhibitors
LT2506840T (lt) Hipoksija sukeliančio faktoriaus inhibitorių naudojimas
IL233415A0 (en) Imidazopyridine derivatives of tyrosine kinase inhibitors, preparations containing them and their uses
PL2314609T3 (pl) Pochodne metastyny i ich zastosowanie
TH0901003723A (th) สารประกอบไตรเอโซโลไพริดินในฐานะสารยับยั้ง pim ไคเนส
TH0901005542B (th) ตัวยับยั้งโปรตีนคิเนส